UK regulators balk at price of Alexion's Soliris


Alexion Pharmaceuticals (ALXN) waits for approval to sell its blockbuster drug Soliris in the UK.

The National Institute for Health and Clinical Excellence (NICE) wants to examine the company's R&D costs for the drug to help it determine the appropriate reimbursement, considering its high cost.

Soliris is the most expensive drug in the world. Annual treatment cost runs £340,000 (US$569,000).

NICE's evaluation of the cost/benefits of the product falls under its new "ultra orphan" disease treatment review process. For Soliris, it has taken three years with no end in sight.

There are ~170 patients in the UK that would be eligible for Soliris, representing a cost to the National Health Service of 58M Pounds ($97M).

Soliris sales were $1.6B last year, with a forecast of $3.4B by 2018.

From other sites
Comments (1)
  • Stkpicr
    , contributor
    Comments (8) | Send Message
     
    Once they get the okay this stock is off to the races. I do not think that the price targets of $195-210 is even close to where this stock will go. I honestly can see this one heading to $240+ by year end if not sooner.
    4 Mar 2014, 11:15 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs